Nephrotic syndrome - A Pipeline Analysis Report

Overview of the drug development pipeline for nephrotic syndrome

Nephrotic syndrome occurs when the cluster of blood vessels present in the kidney, which helps in the filtration of waste and excess water, gets damaged. This causes excessive excretion of protein through the urine and loss of fluid from the body, which may lead to high blood cholesterol levels and high blood pressure. Furthermore, nephrotic syndrome can be recognized through various systems like swelling/edema in feet and ankles. According to CDC, 4.9 million adults in the US in 2016 were diagnosed with kidney disorders, which almost account for 2.0% of the total adult population. Also, according to the NHS in the UK, one in every 50,000 children suffer from nephrotic syndrome. Consequently, with rising incidences of nephrotic syndrome, the need for drug development for nephrotic syndrome will increase in the upcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for nephrotic syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of nephrotic syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AbbVie
• Asahi Kasei Pharma
• ChemoCentryx
• Pfizer
• Retrophin

Therapeutic assessment of the drug development pipeline for nephrotic syndrome by route of administration

• Intravenous/Subcutaneous
• Oral
• Intravenous

The intravenous route of administration (ROA) involves the application of the drug through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for nephrotic syndrome by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for nephrotic syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for nephrotic syndrome?
• What are the companies that are currently involved in the development of drug molecules for nephrotic syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.